Answers are grounded in this paper and cite their sources.
Background: Fatty liver hemorrhagic syndrome (FLHS) is a nutritional-metabolic disorder of laying hens with pathological features analogous to human non-alcoholic fatty liver disease (NAFLD). Aspirin eugenol ester (AEE) has lipid-lowering, anti-inflammatory, and antioxidant activities; however, its protective effects and the underlying molecular mechanisms against FLHS remain unclear. Methods: In this study, we established an in vivo FLHS model in laying hens using a high-energy low-protein diet and an in vitro steatosis model induced by free fatty acids in LMH cells, to explore the hepatoprotective function of AEE. Results: AEE alleviated hepatic lipid accumulation and histopathological lesions, and decreased lipid levels in serum and liver tissue. AEE downregulated the expression of key lipogenic enzymes and upregulated the expression of genes responsible for fatty acid β-oxidation. RNA-seq analysis indicated that the AMPK signaling pathway and autophagy were tightly linked to the hepatoprotective effects of AEE. Treatment with the autophagy activator rapamycin recapitulated the protective effects of AEE, whereas the autophagy inhibitor chloroquine abrogated these beneficial effects. Furthermore, the AMPK inhibitor dorsomorphin partially reversed AEE-mediated liver protection, while the AMPK activator AICAR reproduced the protective effects of AEE. Conclusions: These results indicate that AEE alleviates FLHS in laying hens at least partly through modulation of fatty acid metabolism, likely associated with AMPK/mTOR-mediated autophagy. This work provides mechanistic insights for AEE as a candidate agent for preventing diet-triggered hepatic steatosis.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: